Brown Deborah Margaret 4

What Happened Deborah Margaret Brown, a director of Oncolytics Biotech Inc. (ONCY), acquired 25,000 shares on February 12, 2026 in an open-market purchase (transaction code P). The filing reports a total purchase value of $21,240 (weighted average price ≈ $0.8496, reported as $0.85). This was a direct purchase rather than a grant, exercise, or gift.

Key Details

• Transaction date: 2026-02-12 (filed with the SEC on 2026-02-13 — timely).
• Price: weighted average ≈ $0.8496 per share (reported as $0.85); reported price range for individual trades was $0.835 to $0.85 (see footnote).
• Shares acquired: 25,000; total reported cost: $21,240.
• Shares owned after transaction: not disclosed in the provided filing.
• Footnote: The reported price is a weighted average; the reporting person will provide a breakdown of shares purchased at each price within the $0.835–$0.85 range upon request.
• Transaction type: Open-market purchase (P). No 10b5-1 plan, tax withholding, or option exercise was reported.

Context This was an outright open-market purchase (not an exercise or award). The purchase amount (~$21.2k) is modest in size and, while insider purchases can be viewed positively by investors, they do not prove future company performance.